18F-氟脱氧葡萄糖PET及PET-CT早期诊断肿瘤复发

邢岩 ,  赵晋华

downloadPDF
文章导航 > 国际放射医学核医学杂志  > 2007,  31 > 6: (341-344)  
引用本文:
shu
Citation:
shu

18F-氟脱氧葡萄糖PET及PET-CT早期诊断肿瘤复发

  • 200080 上海, 上海交通大学附属第一人民医院核医学科

    • 通讯作者: 赵晋华, zjh1963@gmail.com

  • 中图分类号: R817.4

18F-fluorodeoxyglucose PET and PET-CT in early detection of cancer recurrent

  • Department of Nuclear Medicine, Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai 200080, China

    • Corresponding author: ZHAO Jin-hua, zjh1963@gmail.com

  • CLC number: R817.4

  • 摘要: 早期探测肿瘤复发可以改善患者的预后,延长其生存期。18F-氟脱氧葡萄糖(18F-FDG)PET能在组织结构变化之前早期探测代谢变化,PET-CT中同机CT提供的融合图像能够对病灶进行精确定位,在早期诊断肿瘤复发方面显示功能与解剖信息互补的作用。除能准确诊断和确定肿瘤复发程度外,18F-FDGPET及PET-CT还能进一步影响患者的治疗。
    Abstract: Early detection of recurrent can improve prognosis and survival of patients with cancer. 18-fluorodeoxyglucose(18F-FDG) PET can detect metabolic changes before structural changes. The fused imaging provided by PET-CT can precisely localize the loci and demonstrate the complementary roles of functional and anatomic assessments in the diagnosis of cancer recurrence. In addition to the accurate diagnosis and definition of the whole extent of recurrent cancer, 18F-FDG PET and PET-CT can impact patients' management.
  • [1] Adam R, Vinet E. Regional treatment of metastasis:surgery of colorectal liver metastases. Ann Oncol,2004,15(suppl 4):iv103-iv106.
    [2] Israel O, Kuten A. Early detection of cancer recurrence:18F-FDG PET/CT can make a difference in diagnosis and patient care. J Nucl Med, 2007, 48(Suppl):28S-35S.
    [3] Schroder FH, Roobol MJ. Words of wisdom. Re:prostate-specific antigen(PSA)and PSA velocity for prostate cancer detection in men aged <50 years. Eur Urol, 2007, 52(3):922.
    [4] Flamen P, Hoekstra OS, Homans F, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer:the utility of positron emission tomography (PET). Eur J Cancer, 2001, 37(7):862-869.
    [5] Hung GU, Shiau YC, Tsai SC, et al. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res, 2001, 21(2B):1375-1378.
    [6] Kalff V. Hicks RJ, Ware RE, et al. The clinical impact of 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer:a prospective study. J Nucl Med, 2002, 43(4):492-499.
    [7] Krestin GP, Steinbrich W, Friedmann G. Recurrent rectal cancer:diagnosis with MR imaging versus CT. Radiology, 1988, 168(2):307-311.
    [8] Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med, 2000, 41(7):1177-1189.
    [9] Torizuka T, Nobezawa S, Kanno T, et al, Ovarian cancer recurrence:role for whole-body positron emission tomography using 2-[fluorine18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging, 2002, 29(6):797-803.
    [10] Zimny M, Siggelkow W, Schroder W, et al. 2-[Fluorine-18]-fluoro-2eoxyglucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol, 2001, 83(2):310-315.
    [11] Kostakoglu L, Agress H, Goldsmith J. Clinical role of FDG PET in evaluation of cancer patients. Radiographics, 2003, 23(2):315-340.
    [12] Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer:additional value for diagnostic imaging and patient management. J Nucl Med, 2003, 44(8):1200-1209.
    [13] Isasi CR, Moadel R, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat, 2005, 90(2):105-112.
    [14] Radan L, Ben-Haim S, Bar-Shalom R, et al. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer, 2006, 107(11):2545-2551.
    [15] Suarez M, Perez-Castejon MJ, Jimenez A, et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med, 2002, 46(2):113-121.
    [16] Aide N, Huchet V, Switsers O, et al. Influence of CA 15-3 blood level and doubling time on diagnostic performances of 18F-FDG PET in breast cancer patients with occult recurrence. Nucl Med Commun, 2007, 28(4):267-272.
    [17] Simcock B, Neesham D, Quinn M, et al. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol, 2006, 103(1):271-276.
    [18] Murakami M, Miyamoto T, Iida T, et al. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer, 2006, 16(Suppl 1):99-107.
    [19] Havrilesky LJ, Kulasingam SL, Matchar DB, et al. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol, 2005, 97(1):183-191.
    [20] Grigsby PW, Siegel BA, Dehdashti F, et al. Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys, 2004, 55(4):907-913.
    [21] Lai CH, Huang KG, See LC, et al. Restaging of recurrent cervical cancer with dual-phase[18F]fluoro-2-deoxy-D-glucose positron emission tomography. Cancer, 2004, 100(3):544-552.
    [22] Lin CT, Yen TC, Chang TC, et al. Role of[18F] fluoro-2-deoxy-Dglucose positron emission tomography in re-recurrent cervical cancer. Int J Gynecol Cancer, 2006, 16(6):1994-2003.
    [23] Kim JH, Czernin J, Allen-Auerbach MS, et al. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer, J Nucl Med, 2005, 46(4):587-595.
    [24] Votrubova J, Belohlavek O, Jaruskova M, et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging, 2006, 33(7):779-784.
    [25] Cohade C, Osman M, Leal J, et al. Direct comparison of 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med, 2003, 44(11):1797-1803.
    [26] Shen YY, Liang JA, Chen YK, et al. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA)in Taiwan. Hepatogastroenterology, 2006, 53(69):348-350.
    [27] Pracchia LF, Chaves AR, Cerci JJ, et al. Metabolic test with fluorine18-fluorodeoxyglucose in staging and cetetion fo residual tumor or recurrence in Hodgkin lymphoma. Clinics, 2007, 62(2):121-126.
    [28] Panizo C, Perez-Salazar M, Bendandi M, et al. Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease medlastinal masses. Leuk Lymphoma, 2004, 45(9):1829-1833.
    [29] Guay C, Lepine M, Verreault J, et al. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evalution. J Nucl Med, 2003, 44(8):1225-1231.
  • [1] 叶慧 , 莫逸 , 谢爱民 , 彭翔 . 18F-氟脱氧葡萄糖PET-CT与99nTc-亚甲基二膦酸盐骨显像诊断转移性骨肿瘤的对比研究. 国际放射医学核医学杂志, 2008, 32(3): 147-150.
    [2] 张悦 . 18F-氟脱氧葡萄糖PET和PET-CT在结直肠癌术后复发或转移中的应用价值. 国际放射医学核医学杂志, 2007, 31(1): 34-36.
    [3] 吕慧清 , 张中民 , 吕仲虹 . 18F-氟代脱氧葡萄糖PET在恶性肿瘤适形放射治疗中的价值. 国际放射医学核医学杂志, 2006, 30(6): 335-337.
    [4] 张玉娜 , 赵晋华 . 18F-氟脱氧葡萄糖PET-CT在头颈部肿瘤临床诊治中的价值. 国际放射医学核医学杂志, 2007, 31(6): 359-362.
    [5] 李剑明 , 李亚明 . 棕色脂肪组织与18F-氟脱氧葡萄糖PET. 国际放射医学核医学杂志, 2007, 31(4): 205-207,231.
    [6] 杨吉刚 , 李春林 . 18F-氟脱氧葡萄糖PET及PET-CT在食管癌中的. 国际放射医学核医学杂志, 2007, 31(1): 31-33.
    [7] 赵德善 , 乔振华 . 18F-氟脱氧葡萄糖PET-CT在淋巴瘤中的应用价值. 国际放射医学核医学杂志, 2007, 31(3): 141-144.
    [8] 宋少莉 , 黄钢 . 18F-氟脱氧葡萄糖PET监测实体瘤放化疗疗效的应用进展. 国际放射医学核医学杂志, 2007, 31(5): 284-288.
    [9] 渠浩 , 王振军 , 陈大志 , 王铁 , 韩进 , 杜燕夫 , 李敏哲 . 18F-氟代脱氧葡萄糖正电子放射导向手术在结直肠癌治疗中的初步应用. 国际放射医学核医学杂志, 2006, 30(3): 145-147.
    [10] 郑磊 , 李前伟 . 18F-氟脱氧葡萄糖PET在原发陛肝细胞癌中的应用. 国际放射医学核医学杂志, 2008, 32(1): 23-26.
    [11] 张悦 , 高硕 . 18F-氟脱氧葡萄糖PET在淋巴瘤中的应用价值. 国际放射医学核医学杂志, 2007, 31(5): 292-295.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  1489
  • HTML全文浏览量:  92
  • PDF下载量:  2
出版历程
  • 收稿日期:  2007-09-10

18F-氟脱氧葡萄糖PET及PET-CT早期诊断肿瘤复发

    通讯作者: 赵晋华, zjh1963@gmail.com
  • 200080 上海, 上海交通大学附属第一人民医院核医学科
  • 收稿日期: 2007-09-10

摘要: 早期探测肿瘤复发可以改善患者的预后,延长其生存期。18F-氟脱氧葡萄糖(18F-FDG)PET能在组织结构变化之前早期探测代谢变化,PET-CT中同机CT提供的融合图像能够对病灶进行精确定位,在早期诊断肿瘤复发方面显示功能与解剖信息互补的作用。除能准确诊断和确定肿瘤复发程度外,18F-FDGPET及PET-CT还能进一步影响患者的治疗。

English Abstract

    全文HTML

参考文献 (29)

目录

    /

    返回文章
    返回

    版权所有©中华医学会   备案号：津ICP备15006720号-3

    地址：天津市南开区白堤路238号电话：86-22-58089989
    86-22-85682389    传真：022-87890607

    本系统由 北京仁和汇智信息技术有限公司 开发 技术支持： info@rhhz.net